CTLA4 and myocarditis: Moreover, it is unknown if there are differences in ICI myocarditis case characteristics and outcomes based on ICI therapeutic target [programmed cell death protein 1 (PD-1), PD ligand 1 (PD-L1), or cytotoxic T-lymphocyte associated protein 4 (CTLA-4)] or with use of combination therapy.